

## ABSTRACT

Cancer Res. 2022 Mar 1;82(5):769-772. doi: 10.1158/0008-5472.CAN-21-3534.

Glioblastoma: The Current State of Biology and Therapeutic Strategies.

Binder ZA(1)(2)(3), O'Rourke DM(1)(2)(3).

### Author information:

(1)Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

(2)Glioblastoma Multiforme (GBM) Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.

(3)Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Over the past two decades, there have been advances in surgical technologies and chemoradiation strategies for glioblastoma, yet durable remissions are rarely seen. As the biological challenges and genetic basis of glioblastoma have become more understood, new therapeutic strategies may lead to more durable clinical responses and long-term remissions. We believe specialized academic centers that form meaningful corporate partnerships to complement basic science infrastructure and use adaptive clinical trial designs will achieve more rapid translation of innovative approaches to glioblastoma. Here we outline the core biological challenges to be overcome in the management of glioblastoma.

©2022 American Association for Cancer Research.

DOI: 10.1158/0008-5472.CAN-21-3534

PMCID: PMC8909691

PMID: 35247893